GenSci 140
Alternative Names: GenSci-140Latest Information Update: 08 Jan 2026
At a glance
- Originator GeneScience Pharmaceuticals
- Class Antineoplastics; Bispecific antibodies; Drug conjugates; Immunoconjugates
- Mechanism of Action DNA topoisomerase I inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 10 Dec 2025 Phase-I clinical trials in Solid tumours (Late-stage disease, Second-line therapy or greater) in China (Parenteral) (NCT07251166)
- 26 Nov 2025 GeneScience Pharmaceuticals plans a first-in-human phase I trial for Solid tumours and Ovarian cancer (Late-stage disease) in China (Parenteral, Injection), in December 2025 (NCT07251166)
- 25 Apr 2025 Preclinical trials in Solid tumours in China (Parenteral), prior to April 2025